Indo Us Biotech Ltd. Announces AGM on Sep 30, 2026; Appoints New Auditors
Indo Us Biotech Ltd. will hold its 22nd AGM on September 30, 2026, via video conference. The Board approved the appointment of M/s. Bhagat & Associates as Statutory Auditors for five years, pending member approval. E-voting will be open from September 27 to September 29, 2026. Book closure is from September 23 to September 30, 2026.
The appointment of statutory auditors for a significant period and the scheduling of the AGM are important corporate governance events that impact the company's operational and compliance framework.
The announcement details routine corporate actions such as scheduling an AGM and appointing auditors, which are standard procedures and do not inherently indicate positive or negative financial performance.
Indo Us Biotech Limited announced the outcome of its Board Meeting held on September 5, 2026. The Board resolved to convene the 22nd Annual General Meeting (AGM) on Wednesday, September 30, 2026, at 02:30 PM, which will be conducted through video conferencing (VC) or other Audio-Visual Means (OAVM). The financial year under review for the AGM is ended March 31, 2026.
Key decisions made include the approval of the draft notice for the AGM and the draft Directors' Report for the financial year ended March 31, 2026. The Book Closure Date for the AGM is set from September 23, 2026, to September 30, 2026, inclusive. The e-voting period will commence on Sunday, September 27, 2026, at 9:00 AM and conclude on Tuesday, September 29, 2026, at 5:00 PM. The cut-off date for determining voting eligibility is September 23, 2026.
Furthermore, the Board approved the appointment of M/s. Bhagat & Associates, Chartered Accountants, as the Statutory Auditors for a period of five consecutive years, commencing from the conclusion of the upcoming 22nd AGM until the conclusion of the 27th AGM. This appointment is subject to the approval of the Members at the AGM. M/s. Amrish Gandhi & Associates, Practising Company Secretary, has been appointed as the scrutinizer for the e-voting process.
What to do with a filing like this
Indo Us Biotech Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indo Us Biotech Limited. Read the original for the full detail.